Don’t wait for symptoms of persistent bloating, pelvic pain or feeling full quickly to investigate for ovarian cancers. Early detection is your key to treat this silent threat. HE4, a key biomarker, combined with CA-125 and imaging, can spot ovarian tumours sooner, when treatment is most effective. Arrange an Early Detection of Ovarian tumour Panel Test with us.
While ovarian cancer is often called a “silent killer” due to vague early symptoms, proactive screening offers a critical advantage. The combined Early Detection Panel – assessing HE4 (a newer biomarker showing promise in early stages), alongside CA-125 and transvaginal ultrasound – significantly improves sensitivity compared to single tests alone.
This multi-modal approach is particularly valuable for women at elevated risk, including those with a family history of ovarian/breast cancer, BRCA gene mutations, or a personal history of endometriosis. Scheduling regular screening, especially if you have risk factors, allows for potential detection when tumours are most treatable, often before symptoms manifest. Early-stage diagnosis dramatically improves treatment success and survival rates. Don’t rely on symptoms; discuss a personalized screening plan with your gynaecologist today.
